Cerus Corporation (CERS) : During the past 4 weeks, traders have been relatively bearish on Cerus Corporation (CERS), hence the stock is down -1.83% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.49% relative to the S&P 500. The 4-week change in the price of the stock is -2.36% and the stock has fallen -0.32% in the past 1 week.
The stock has recorded a 20-day Moving Average of 0.24% and the 50-Day Moving Average is 5.96%.The 200 Day SMA reached 3.01%
Cerus Corporation (NASDAQ:CERS): After opening at $6.13, the stock dipped to an intraday low of $6.01 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $6.25 and the buying power remained strong till the end. The stock closed at $6.21 for the day, a gain of 1.47% for the day session. The total traded volume was 923,114. The stocks close on the previous trading day was $6.21.
Cerus Corporation (CERS) : The highest short term price target forecast on Cerus Corporation (CERS) is $10 and the lowest target price is $9. A total of 5 equity analysts are currently covering the company. The average price of all the analysts is $9.7 with a standard deviation of $0.45.
Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Companys INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries, including the United States, certain countries in Europe, The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.